Longevity Focus The Longevity Fund, now operating as age1, is a dedicated longevity-focused venture firm with a track record of backing breakthrough biotech founders and advancing aging-related programs to the clinic, indicating a strong potential for strategic partnerships and co-investment opportunities with biotech startups and research institutions.

Funding Momentum Recent capital activity includes a $100M Series C into Loyal and a $21M seed investment into Aerska, highlighting active deal sourcing and a readiness to scale portfolio companies; this suggests opportunities to engage portfolio companies for follow-on funding, strategic collaborations, and clinical development partnerships.

Expansion Signals Age1 represents the next generation of longevity investing, signaling ongoing growth and potential need for value-add services, advisory collaborations, and ecosystem partnerships with other investors, CROs, and regulatory affairs experts to accelerate portfolio milestones.

Technology Footprint The firm’s current tech stack and online presence indicate a modern, digitally-enabled operation; sales outreach can leverage insights from their digital channels and content to tailor engagement and identify co-marketing or investor-relations opportunities with aligned tech and data capabilities.

Financial Health Clues With reported revenue in the low single digits and a high-impact, high-visibility portfolio, there is potential to offer early-stage fundraising support, advisory services, or wealth/deal-sourcing partnerships that align with their growth trajectory and fundraising cadence.